FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes
FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes
The U.S. Food and Drug Administration is preparing to roll back restrictions that have limited the availability of compounded peptide therapies, according to reporting by The New York Times. The move aligns with Health and Human Services Secretary Robert F. Kennedy Jr.'s longstanding advocacy for broader access to peptides and other alternative health treatments.
Background
In recent years, the FDA placed several popular peptides — including BPC-157, TB-500, and various growth hormone secretagogues — on its list of substances that compounding pharmacies cannot use. These restrictions frustrated both clinicians who prescribed peptide therapies and the growing number of patients who reported benefits from them.
What's Changing
The expected policy shift would restore the ability of compounding pharmacies to prepare certain peptide formulations, making them more accessible to patients through legitimate medical channels. This is seen as a significant win for the peptide therapy community.
Industry Reaction
The news has been met with enthusiasm from peptide advocates and cautious optimism from researchers. While some medical professionals have raised concerns about insufficient long-term safety data, supporters argue that restricting access has driven consumers toward unregulated online markets.
What It Means
This development marks a turning point in the ongoing debate over how the United States regulates peptide therapies. With the FDA apparently shifting toward a more permissive stance, the peptide industry could see rapid growth — but also increased scrutiny regarding quality control and patient safety.
Source: The New York Times, March 31, 2026